[The guidelines of prevention and treatment for chronic hepatitis B] - PubMed

[Article in Chinese]

• PMID: 16491521

Guideline

[The guidelines of prevention and treatment for chronic hepatitis B]

[Article in Chinese]

Chinese Society of Hepatology, Chinese Medical Association et al. Zhonghua Gan Zang Bing Za Zhi. 2005 Dec.

Similar articles

• [The guideline of prevention and treatment for chronic hepatitis B (2010 version)].

  Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):13-24. doi: 10.3760/cma.j.issn.1007-3418.2011.01.007. Zhonghua Gan Zang Bing Za Zhi. 2011. PMID: 21272453 Chinese. No abstract available.

• Guideline on prevention and treatment of chronic hepatitis B in China (2005).

  Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese Society of Hepatology, Chinese Medical Association, et al. Chin Med J (Engl). 2007 Dec 20;120(24):2159-73. Chin Med J (Engl). 2007. PMID: 18167196 No abstract available.

• [Chronic hepatitis B virus infection, its treatment and prevention].

  Zhuang H. Zhuang H. Zhonghua Gan Zang Bing Za Zhi. 2005 May;13(5):324-5. Zhonghua Gan Zang Bing Za Zhi. 2005. PMID: 15918962 Chinese. No abstract available.

• National Institutes of Health consensus development conference statement: management of hepatitis B.

  Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT. Sorrell MF, et al. Hepatology. 2009 May;49(5 Suppl):S4-S12. doi: 10.1002/hep.22946. Hepatology. 2009. PMID: 19399804 No abstract available.

• The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting.

  Barclay S, Pol S, Mutimer D, Benhamou Y, Mills PR, Hayes PC, Cameron S, Carman W. Barclay S, et al. J Clin Virol. 2008 Apr;41(4):243-54. doi: 10.1016/j.jcv.2007.11.017. Epub 2008 Jan 18. J Clin Virol. 2008. PMID: 18203658 Corrected and republished. No abstract available.

Cited by

• Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

  Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, Wang YL, Li DQ. Zhou YM, et al. World J Gastroenterol. 2008 Jan 28;14(4):632-5. doi: 10.3748/wjg.14.632. World J Gastroenterol. 2008. PMID: 18203300 Free PMC article.

• Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis.

  Wu YL, Shen CL, Chen XY. Wu YL, et al. World J Clin Cases. 2019 Jul 26;7(14):1784-1794. doi: 10.12998/wjcc.v7.i14.1784. World J Clin Cases. 2019. PMID: 31417924 Free PMC article. Review.

• MicroRNA-146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin-6.

  Yang Z, Peng Y, Yang S. Yang Z, et al. Exp Ther Med. 2019 Jun;17(6):4670-4676. doi: 10.3892/etm.2019.7490. Epub 2019 Apr 16. Exp Ther Med. 2019. PMID: 31086599 Free PMC article.

• The regulatory role of IL-6R in hepatitis B-associated fibrosis and cirrhosis.

  Chen Y, Yang S, Peng Y, Yang Z. Chen Y, et al. Braz J Med Biol Res. 2017 Sep 21;50(11):e6246. doi: 10.1590/1414-431X20176246. Braz J Med Biol Res. 2017. PMID: 28953986 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Chinese Medical Association Publishing House Ltd.